Form 483

Tris Pharma Inc. Form 483, 2017-03-20

FDA issued a Form 483 to Tris Pharma Inc. on 2017-03-20 with 18 public-safe observations.

483· Form 483 issuedHuman Drugs18 observations

Tris Pharma Inc. · Monmouth Junction, United States · Issued March 20, 2017

Overview

  • 18 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

20 Mar 2017
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Adetutu M Gidado

20 Mar 2017
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Adetutu M Gidado

20 Mar 2017
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Adetutu M Gidado

20 Mar 2017
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Adetutu M Gidado

20 Mar 2017
21 CFR 211.165(e)

Test methods

Cited by Adetutu M Gidado

Inspected site

TPTris Pharma Inc.Monmouth Junction, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations3x
21 CFR 211.160(a)Cited across public-safe Form 483 observations3x
21 CFR 211.165(e)Cited across public-safe Form 483 observations3x
21 CFR 211.22(a)Cited across public-safe Form 483 observations3x
21 CFR 211.22(d)Cited across public-safe Form 483 observations3x
21 CFR 211.80(b)Cited across public-safe Form 483 observations3x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 18 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere